RT Journal Article
T1 Human Neural Stem Cells for Cell-Based Medicinal Products.
A1 Fernandez-Muñoz, Beatriz
A1 Garcia-Delgado, Ana Belen
A1 Arribas-Arribas, Blanca
A1 Sanchez-Pernaute, Rosario
K1 NSC
K1 advanced therapies
K1 central nervous system
K1 efficacy
K1 neural precursors
K1 neural progenitors
K1 quality control
K1 regenerative medicine
K1 safety
K1 scalability
AB Neural stem cells represent an attractive tool for the development of regenerative therapies and are being tested in clinical trials for several neurological disorders. Human neural stem cells can be isolated from the central nervous system or can be derived in vitro from pluripotent stem cells. Embryonic sources are ethically controversial and other sources are less well characterized and/or inefficient. Recently, isolation of NSC from the cerebrospinal fluid of patients with spina bifida and with intracerebroventricular hemorrhage has been reported. Direct reprogramming may become another alternative if genetic and phenotypic stability of the reprogrammed cells is ensured. Here, we discuss the advantages and disadvantages of available sources of neural stem cells for the production of cell-based therapies for clinical applications. We review available safety and efficacy clinical data and discuss scalability and quality control considerations for manufacturing clinical grade cell products for successful clinical application.
YR 2021
FD 2021-09-09
LK http://hdl.handle.net/10668/18548
UL http://hdl.handle.net/10668/18548
LA en
DS RISalud
RD Apr 6, 2025